



Europass Curriculum Vitae

Informatii personale

Nume / Prenume

Tiu, Cristina

Adresa

Spitalul Universitar de Urgenta Bucuresti, Clinica de Neurologie,, Splaiul Independentei 169, sector 5,
050098, Bucuresti, Romania

Telefon

(40-21) 318 05 02

Mobil:

Fax

(40-21) 312 81 02

E-mail

cristina.tiu@umfcd.ro

Nationalitate

Romana

Data nasterii

Sex

Feminin

Domeniul profesional

Neurologie

Experienta profesionala

Date

Din Februarie 2022- Profesor universitar UMF Carol Davila"
Din Martie 2007 : Conferentiar universitar UMF "Carol Davila"
Din Martie 2000 pana in Martie 2007: Sef de lucrari UMF "Carol Davila"
Din Martie 1993 pana in Martie 2000: Asistent universitar UMF "Carol Davila"

Ocupatie sau functia actuala

Profesor universitar, sef sectie Neurologie II, Sef disciplina Neurologie Clinica Neurologie SUUB,
Departamentul 6, Neurostiinte clinice UMF "Carol Davila"

Principalele activitati si responsabilitati

Activitate didactica cu studentii si rezidentii
Activitate didactica pentru cursuri postuniversitare
Activitate clinica de diagnostic si tratament al pacientilor
Explorari functionale – ultrasonografie Doppler
Activitate de cercetare, conducator doctorate
Activitate de coordonare programe naționale de sănătate

Numel si adresa angajatorului

Universitatea de Medicina si Farmacie "Carol Davila"
Dionisie Lupu 37, sector 1, 70183, Bucuresti, Romania
Tel: (40-21) 318 07 18 , Website : <http://www.uni-davila.ro>
Spitalul Universitar de Urgenta Bucuresti, Clinica de Neurologie
Splaiul Independentei 169, sector 5, R- 76251, Bucuresti, Romania
Tel : (40-21) 318 05 20, Website: <http://www.suub.ro>

Domeniul de activitate

Medicina, Neurologie

Educatie si instruire

Date

Octombrie 2008 -iunie 2012- European Master in Stroke, Danube University, Krems, Austria
20- 25 Aprilie 2001, 2nd EFNS European Cooperation Neurology Workshop, Trest, Czech Republic
13- 19 Aprilie 2000, 1st EFNS European Cooperation Neurology Workshop, Trest, Czech Republic
Mai 2000, EFNS Teaching Course in Tg Mures
Mai – Nov 1998: Stagiul clinic la Centre Hospitalier Universitaire, Amiens, France
1991- 1993: secundariat in Neurologie, la SUUB, Romania
Nov. 1987 – Ian. 1991: stagii clinice de 6 luni in medicina interna, chirurgie, ginecologie, pediatrie,
boli infectioase si medicina de familie, la Spitalul Municipal Tg. Jiu, Romania
Sep 1981 - Sep. 1987: studenta la UMF "Carol Davila", Bucuresti, Romania

Titluri si calificari obtinute

Medic, 1987
 Medic specialist neurolog, 1994
 Medic primar neurolog 1998
 Doctor in stiinte medicale, 2001 pentru teza: "Corelatii clinico- imagistice la pacientii cu ischemie cerebrala cronica"
 European Master of Sciences in Stroke Medicine, Danube University, Krems, Austria 2012, Teza "Subtypes of stroke in metabolic syndrome"
 Conducator de doctorate- confirmare prin Ordin ME Nr 5927/23.12.2021

Domenii principal de interes

Domeniul principal: bolile cerebrovasculare
 Alte domenii: boli inflamatorii si demielinizante ale sistemului nervos central

Numele si tipul organizatiei care a furnizat educatia si instruirea

Universitatea de Medicina si Farmacie "Carol Davila"
 Dionisie Lupu 37, sector 1, 70183, Bucuresti, Romania
 Tel: (40-21) 318 07 18, Website : <http://www.uni-davila.ro>

Abilitati si competente personale

Limba materna

Romana

Alte limbi straine

Autoevaluare

Nivel european (*)

engleza

franceza

Intelegere				Vorbire				Scriere	
Ascultare		Citire		Dialog		Discurs narativ			
C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user
C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user	B1	Independent user

(*) Common European Framework of Reference for Languages

Aptitudini si abilitati sociale

- Spirit de echipa
 Abilități crescute în comunicare (absolvent curs de pregătire "Business Presentation Programme", 15-16 Iulie 2006, organizat de TMI România)

Abilitati si competente organizatorice

- leadership
- bun organizator
- Presedinte al Societatii de Neurologie din Romania pentru perioada 2021-2025
- Presedinte al Colectivului de lucru din cadrul Ministerului Sanatatii pentru Actiunea Prioritara AVC acute, incepand cu 2015
- Organizator si coordinator al Retelei Nationale de Accidente vasculare cerebrale
- Membru al Steering Committee pentru Stroke Action Plan for Europe al European Stroke Organisation din 2019
- Coordonator al Programului de Educație Medicală Continuă al Federației Mondiale de Neurologie în România, incepand cu 2005
- Membru al comitetului de organizare al EFNS Teaching Course, București, 20-22 octombrie, 2007
- Membru al comitetelor de organizare în cadru a numeroase conferințe medicale, incluzand Congresul anual al Societatii de Neurologie din Romania
- Experiență crescută în management-ul unei echipe sau a unui proiect:
 - o coordonator a 3 Grant-uri naționale de cercetare 1999-2001, 2006-2008, 2014-2017- vezi lista granturilor
 - o work package leader la un grant international (IRENE COST)
- Peste 25 ani de experiență în studii clinice (de fază II, III și IV)- vezi lista studiilor clinice

Abilitati tehnice si competente	Competenta in Neurosonologie din 2000 Program de training 1993 "Ultrasonografia arterelor cervicale și cerebrale" la Institutul de Boli Cerebrovasculare "Vlad Voiculescu", București, România Cursuri avansate de neurosonologie la Conferința Societății de Neurosonologie și Hemodinamică Cerebrală în 2001 (Lisabona, Portugalia), 2002 (Berna, Elveția), 2004 (Wetzlar, Germania), 2006 (Düsseldorf, Germania) Peste 30 ani de experiență clinică – Organizator și autor al unui curs post-universitar de 3 săptămâni în Neurosonologie, organizat anual în cadrul Universității de Medicină și Farmacie "Carol Davila" începând din 2004 Co- organizator al Primului curs de "Organizare si management al Unitatilor de AVC acute" in cadrul UMF "Carol Davila" Colaborator permanent al cursului de ultrasonografie vasculara din cadrul UMF "Carol Davila" București, coordonat de către Conf. Dr. Roxana Darabonț Coordonator a șase cursuri de instruire teoretică și practică în Brașov, Sibiu, Galați, București, Craiova pentru tratamentul fibrinolitic al accidentului vascular cerebral
Abilitati de utilizare a calculatorului	- utilizator avansat Office™ (Word™ ,Excell, Power Point™)
Permis de conducere	Categoria B
Informații adiționale	Statut marital: casatorita, 2 copii (33 ani, 31 ani) Membru al următoarelor organizații: - Societatea de Neurologie din Romania (SNR). Presedinte ales al SNR pentru intervalul 2021-2025 European Stroke Organization , membru in Steering Committee pentru Stroke Action Plan for Europe, 2018-2030 Delegat al SNR pentru relatia cu Academia Europeana de Neurologie Societatea Europeană de Neurosonologie și Hemodinamică Cerebrală

1. **Improvements in life expectancy in diabetes type I patients in the last six decades**, Ioacara S, Lichiardopol R, Ionescu – Targoviste C, Cheta D, Sabau S, Guja C, Farcasan E, **C. Tiu**, Diabetes Research and Clinical Practice, 2009, Nov 86(2) :145-51 DOI: [10.1016/j.diabres.2009.08.012](https://doi.org/10.1016/j.diabres.2009.08.012)
2. **Particular aspects in patients with coronary heart disease and vascular cognitive impairment**. O. Bajenaru, F. Antochi, **C. Tiu**, Journal of Neurological Sciences 299 (2010) 49- 50, DOI: [10.1016/j.jns.2010.08.049](https://doi.org/10.1016/j.jns.2010.08.049)
3. **Improvements in life expectancy in adult type 2 diabetes patients in the last six decades** Ioacara, Sorin; Guja, Cristian; Ionescu -Tirgoviste, Constantin; Fica, Simona; Sabau, Sorin; Radu, Stefania; Micu, Andrei; **C. Tiu**, Published in Diabetes Research and Clinical Practice on June 01, 2011 DOI:<https://doi.org/10.1016/j.diabres.2011.03.022>
4. **„Transient Global Amnesia After Cerebral Angiography With Iomeprol – A Case report”** – C. Tiu, E. Terecoasa, N. Grecu, B. Dorobat, A. Marinescu, O. Bajenaru – Medicine – Volume 95, Number 19, May 2016 doi: [10.1097/MD.0000000000003590](https://doi.org/10.1097/MD.0000000000003590)
5. **Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response** Rodica Bălașa , Smaranda Maier, Septimiu Voidăzan, Adina Huțanu, Zoltan Bajko, Anca Moțățăianu, Brândușa Țilea and **C. Tiu**, CNS & Neurological Disorders - Drug Targets, 2017, vol 16, nr 1, pag 93-101 DOI: [10.2174/1871527315666160615110739](https://doi.org/10.2174/1871527315666160615110739)
6. **“Etiologic classification of ischemic stroke: Where do we stand?”** – R.A. Radu, E. Terecoasa, O.A. Bajenaru, **C.Tiu** – Journal of Neurology and Neurosurgery – 2017, 159: 93-106 Accession Number: 28609703 DOI: [10.1016/j.clineuro.2017.05.019](https://doi.org/10.1016/j.clineuro.2017.05.019)
<https://www.ncbi.nlm.nih.gov/pubmed/28609703>
7. **“Opsoclonus-Myoclonus Syndrome Associated With West-Nile Virus Infection: Case Report and Review of the Literature”** - Radu RA, Terecoasă EO, Ene A, Băjenaru OA, **C.Tiu** – Frontiers in Neurology – 2018 - 9:864. DOI: [10.3389/fneur.2018.00864](https://doi.org/10.3389/fneur.2018.00864)
8. **Therapeutic challenges in patients with non-cardioembolic acute ischemic stroke in need of double antiplatelet therapy for coronary artery disease”**. Roxana Oana Darabont, Claudiu Stoicescu, Cristina Tiu. American Journal of Therapeutics 26, e213-e221 (2019) DOI: [10.1097/MJT.0000000000000924](https://doi.org/10.1097/MJT.0000000000000924)
9. **”Stroke mortality rates and trends in Romania, 1994-2017”**. Sorin Ioacara, C. Tiu, Cristina Panea, Horia Nicolae, Elisabeta Sava, Sorina Martin, Simona Fica-Journal of stroke and cerebrovascular diseases, vol 28, no 12 (December) 2019 DOI: [10.1016/j.jstrokecerebrovasdis.2019.104431](https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104431)
10. **Effectiveness and Safety Profile of Ginkgo Biloba Standardized Extract (EGb761®) in Patients with Amnesic Mild Cognitive Impairment** Ovidiu Băjenaru, Gabriel Prada, Florina Antochi, Cătălin Jianu, Cătălina Tudose, Adina Cuciureanu, Any Axelerad Docu, Valérie Perrot, Madalina Avram, **C. Tiu** CNS & Neurological Disorders - Drug Targets, 2021 DOI: [10.2174/1871527320666210208125524](https://doi.org/10.2174/1871527320666210208125524)

27 mar 2023

Lista granturilor si a contractelor de cercetare

Anexa la CV

Contract internațional/work package leader

1. COST – European Cooperation in Science and Technology – CA 18118
Coordonator workpackage 2

Contract/grant național – director

1. Program VIASAN : Studiul reactivității vasomotorii la pacienți cu suferință cerebrală ischemică

Contract 150/29.10.2001

Valoare : 1.300.000 mii ROL

2. Program CEEEX : Cuantificarea efectului simvastatinei asupra inflamației sistemice, a modificărilor cardiace subclinice și aterosclerozei precoce în artrita reumatoidă, CESIA

Contract 114/2006, responsabil partener

Valoare : 200.000 RON

3. Program PN II. Proiect tip PCCA tip 2, CERMO- Aparat pentru monitorizarea reactivității EEG la stimuli externi în timpul comei. Contract nr 129/2012, responsabil partener

Valoare 2,249.598 lei

Contract/grant național – membru în echipa de cercetare

1. Program CEEEX : Mecanismele moleculare, celulare și integrative ale durerii. Implicații clinice Contract 686/2005
Valoare : 567.000 RON
2. Proiectul de cercetare 3DDTI – “Imagini ale traiectelor nervoase (*Diffusion Tensor Imaging*) integrate unui model anatomic 3D – instrument de diagnostic și tratament” - parteneriat între Spitalul Clinic “Prof. Dr. Th. Burghel”, Spitalul Clinic “Bagdasar-Arseni”, Spitalul Universitar de Urgență București, Departamentul de Bioinginerie și biotehnologie – Universitatea POLITEHNICA București, SC Medix Co SRL, grant de cercetare obținut prin competiție în valoare de , 2008-2011, participare ca expert neurolog – *membru în echipa de cercetare*
3. NERMO - PN-III-P2-2.1-PTE-2016-0114 – Monitor pentru reactivitatea neurofiziologică Neurophysiological Monitor - grant de cercetare obținut prin competiție, în cadrul Programului Parteneriate, 2016-2018 (30.09.2018), SC TERMOBIT PROD – coordonator, UMF “Carol Davila”, Spitalul Universitar de Urgență București
4. Dezvoltarea infrastructurii publice de cercetare, dezvoltare și crearea de noi infrastructuri – AngioNET – SMIS 107124

Studii multicentrice internaționale – investigator principal

1. C. Tiu, F. Antochi, O. Băjenaru

Studiul REFLEX, A Phase III, randomized, double-blind, placebo controlled, multicenter clinical trial of REBIF new formulation (44mcg tid and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis (REFLEX) Protocol 27025, site 155. 2012- 2014

2. C. Tiu, F. Antochi, O. Băjenaru

Studiul REFLEXION, Double blind extension of the study 27025 (REFLEX) to obtain long-term follow up data in subjects with clinically definite MS and subjects with a first demyelinating event at risk of converting to MS, treated with REBIF new formulation. Protocol 28981, site 155. 2014-2016

3. Băjenaru O, Tiu C, Roceanu A, Antochi F, Nistor R, Terecoasa E, Ribigan A

OPTIMUM-LT: Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis (Study AC-058B303)

4. C. Tiu, F. Antochi, A. Roceanu

Comprehensive assessment of **Erenumab** efficacy in subjects with high frequency episodic migraine, with at least 1 previously failed preventive treatment: a global, double blind, placebo-controlled Phase 4 study. Protocol number 20190008, site

5. C.Tiu, E. Terecoasă

IMPROVE (International Multicenter Patent Foramen Ovale and Stroke Registry) studiu internațional, multicentric, observational, de cohortă. Sponsor investigator: Dr. Luciano A. Sposato, MD, MBA, FRCPC London Health Sciences Center, University Hospital, London Ontario

Studii multicentrice internaționale – membru în echipa de cercetare

1. Bajenaru O, Tiu C, Marinescu D
Studiul APRES (ACAT – inhibition Plaque Regression Study)
Investigator principal PU Witte, IMFORM GmbH, Germania 2003 – 2005
2. Bajenaru O, Tiu C, Panea C, Antochi F, Mandruta I
BRAVO – Blockade of the GPIIb/IIIa receptor to avoid vascular occlusion
2000, contract cu SmithKline Beecham

6. Bajenaru O, Tiu C, Panea C, Roceanu A, Marinescu D

TVP – 1012/122(LARGO) – A multicenter double – blind , double – dummy, randomized, placebo and entacapone – controlled , parallel group study, for the efficacy,, tolerability and safety of rasagiline mesylate in levo dopa treated Parkinson's disease patients with motor fluctuations, 2001 – 2002; contract de cercetare cu TEVA , Israel, 2002 –2003

7. Bajenaru O, Tiu C, Panea C, Roceanu A

TVP – 1012/123 An active extension of the TVP 1012/122 study, A multicenter double – blind , double – dummy, randomized, placebo and entacapone – controlled , parallel group extension study, to evaluate the long term efficacy,, tolerability and safety of rasagiline mesylate in levo dopa treated Parkinson's disease patients with motor fluctuationssv contract de cercetare cu TEVA , Israel, 2002 –2003

8. Bajenaru O, Panea C, Tiu C, Antochi F

Essai 1073, Etude de l'activite du Modafinil sur la recuperation fonctionnelle et la fatigue de patients ayant presente un accident vasculaire cerebrale ischemique recent. Etude double aveugle – groupe paralleles versus placebo, 2001 – 2004 ,

Contract de cercetare cu laboratoarele Lafon/ Franta

9. Bajenaru O, Tiu C, Panea C, Antochi F,

Prevent – Prospective evaluation of Dalteparin efficacy for prevention of VTE in immobilized patients trial, 2001 – 2002

Contract cu Pharmacia Upjohn

10. Bajenaru O, Tiu C, Antochi F, Roceanu A

666 – CNS – 0075 – 0022;Phase III, Double blind, placebo controlled, Randomized study comparing the efficacy, safety and tolerability of Sumanitrolol versus placebo or Ropinirole as adjuvant to LevoDopa in patients with advanced Parkinson Disease, 2001 – 2003

Contract de cercetare cu Pharmacia UpJohn

11. Bajenaru O, Tiu C, Antochi F, Roceanu A

666 – CNS – 0075 – 0019 Open label , long term, flexible dose study of safety , tolerability and therapeutic response of PNU – 95666E in patients with Parkinson Disease, 2003- 2004
contract cu Pharmacia UpJohn

12. Bajenaru O, Tiu C, Antochi F

38- 00240-704, A phase III, double blinded parallel group, placebo controlled, clinical study for evaluating of the efficacy of EGB 761/ Tanakan 240 mg in the recovery of neurological impairment following ischemic stroke, 2003 -2005

Contract cu Beaufour – Ipsen Group, Franta

13. Bajenaru O, Tiu C, Antochi F
AGATHA – A Global Atherothrombosis Assessments, 2002 – 2003
 Contract cu Sanofi Synthelabo, Franta

14. Bajenaru O, Tiu C, Antochi F, Marinescu D, Ene A
Reach Registry – reduction of atherothrombosis for continued health
 2003 – 2006, contracto cu Sanofi Synthelabo, Franta

15. Bajenaru O, Tiu C, Antochi F, Popescu B.O.
CERE-HST- Cerebrolysine in Hemoragic Stroke
 Contract de cercetare cu EBEWE Pharma Austria, sept 2003 – mar 2006

16. Bajenaru O, Tiu C, Marinescu D
Study 24810 – A multicenter, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hINF beta-1a (Rebif) using clone 484-39 in the treatment of subjects with Relapsing Remitting Multiple Sclerosis. 2004-2005

17. Bajenaru O, Tiu C, Antochi F, Roceanu A, Popescu B.O
GA/9010(Precise) – A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting with a Clinically Isolated Syndrome (CIS), 2004 – 2010
 Contract de cercetare cu TEVA, Israel

18. Bajenaru O, Tiu C, Petrescu S
GA9011 FORTE– A multi-center open-label study to evaluate the efficacy, tolerability and safety of glatiramer acetate (GA) in combination with methylprednisolone treatment for 6 months followed by GA alone for 6 months, in subjects with relapsing-remitting multiple sclerosis (R-R MS) with active disease on MRI. 2004 – 2005
 Contract de cercetare cu TEVA , Israel

19. Bajenaru O, Tiu C, Roceanu A, Petrescu S.
TV 5010/202 – A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis 2004 – 2006
 Contract de cercetare cu TEVA, Israel

20. Bajenaru O, Tiu C, Antochi F, Roceanu A
TVP-1012/500 a multicenter, double-blind, randomized start, placebo-controlled, parallel group study to assess Rasagiline as a disease modifying therapy in early Parkinson`s disease subjects. 2005 – 2007
 Contract de cercetare cu TEVA, Israel

21. Bajenaru O, Tiu C, Popescu B, Lazar I
Axonyx – A randomised, double – blind, placebo controlled study to evaluate the safety and efficacy of two different doses of phenserine tartrate in patients with mild to moderate Alzheimer disease, 2005, Axonyx Inc

22. Bajenaru O, Tiu C, Antochi F, Iana G
BHT – 3009-03; Imunotherapy in relapsing remitting multiple sclerosis. Bayhill Therapeutics

23. Bajenaru O, Tiu C, Antochi F, Roceanu A, Popescu B
PERFORM – studiu international, randomizat, dublu orb, pe doua grupuri paralele comparand terutroban 30 mg/zi cu aspirina 100 mg/zi, administrate oral pe o perioada medie de trei ani. 2006 – 2010
 Contract cu Institut de Recherches Internationales Servier

24. Bajenaru O, Tiu C, Antochi F
BRIGHT – Betaferon versus Rebif investigating higher tolerability
 2004- 2005, Schering AG, Germania

25. Bajenaru O, Tiu C, Antochi F
Cogni – MS ; assessment of cognitive function in patients with multiple sclerosis
 2006- 2008, Schering AG, Germania

26. Bajenaru O, Tiu C, Antochi F

A double blind, placebo controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis
Antisense Therapeutics Ltd.

27. Băjenaru O, C. Tiu, A. Roceanu, F. Antochi

Extensie ADAGIO TVP 1012/500 – Disease modification study – TEVA Pharmaceutical

28. Bajenaru O, Tiu C, Antochi F, Terecoasa E, Ribigan A

SOCRATES - Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (Protocol No. D5134C00001)

29. Bajenaru O, Tiu C, Roceanu A, Antochi F

CFTY720D2301 – A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel- group study comparing efficacy and safety of FTY720 1,25 and 0,5 mg administrated orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis, phase III - Sponsor : NOVARTIS, Investigator Meeting – Crowne Plaza Hotel, Bucharest, Romania, March 1st, 2007-2009;

30. Bajenaru O, Tiu C, Roceanu A, Antochi F

EXTENSIE CFTY720D2301E1 – extensie CFTY720D2301 A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel- group study comparing efficacy and safety of FTY720 1,25 and 0,5 mg administrated orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis, phase III - Sponsor: NOVARTIS, 2009-2011

31. O. Băjenaru, F. Antochi, C. Tiu, A. Roceanu

109-MS-301, BG00012 – A Randomized, Double-Blind, Placebo-Controlled, Dose-Comparasion Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis (Un Studiu Randomizat, Multicentric, Dublu-Orb, Controlat Placebo, cu Comparare de Doze pentru a stabili Eficienta si Siguranta BG00012 la Subiectii suferinzi de Scleroză Multiplă Recidivantă-Remitentă – Studiul nr. 109-MS-301, Produsul : BG00012) – debutat 2007- 2011

32. O. Băjenaru, F. Antochi, C. Tiu, A. Roceanu

109-MS-303 – “A dose-blind multicenter, extension study to determine the long-term safety and efficacy of two doses of BG00012 monotherapy in subjects with RR-MS”, debutat 2009

33. O. Băjenaru, F. Antochi, C. Tiu, A. Roceanu

ADVANCE – 105 MS 301 – “A multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis” – A Phase III Clinical Trial, Sponsor Biogen

34. O. Băjenaru, F. Antochi, C. Tiu, A. Roceanu

Protocol **105MS302-ATTAIN**: An Extension Study of PEGylated Interferon Beta-1a in Relapsing MS”- “ A dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis” – October 15 2011, Paris

35. O. Băjenaru, F. Antochi, C. Tiu, A. Roceanu

GALA - A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in a double-blind design; Protocol No: MS-GA-301 (GALA Study) – finalizat 2017

36. O. Băjenaru, F. Antochi, C. Tiu, A. Roceanu, R. Nistor

CONCERTO LAQ-MS-305 – “A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0,6 mg/day or 1,2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)”- rol examining, Investigator Meeting Munich, Germany, February 19, 2013 – finalizat 2017

37. Bajenaru O, Tiu C, Antochi F, Terecoasa E, Ribigan A

THALES - The Acute Stroke or Transient Ischaemic Attack Treated with Ticagrelor and ASA [acetylsalicylic acid] for Prevention of Stroke and Death (Protocol No. D5143C00003)

38. Bajenaru O, Tiu C, Roceanu A, Antochi F, Nistor R

BAF - A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary

progressive multiple sclerosis followed by extended treatment with open-label AF312 (**Protocol No. CBAF312A2304**)

39. Bajenaru O, Tiu C, Roceanu A, Antochi F,

EFC6260, TOPIC, An international, multi-center, randomized, double-blind, placebo-controlled parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide once daily versus placebo, in patients with a first clinical episode suggestive of multiple sclerosis, Sponsor Sanofi- Aventis, site 7806

40. Bajenaru O, Tiu C, Roceanu A, Antochi F, Nistor R, Terecoasa E, Ribigan A

OPTIMUM – Multicenter double-blind, active-comparator, superiority randomized clinical trial study, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis (Study AC-058B301)

41. Băjenaru O, Antochi F, Tiu C, Roceanu A, Nistor R, Gavan C

ENSEMBLE PLUS, MA30143, studiu deschis, cu un singur brat pentru evaluarea eficacității și siguranței ocrelizumab la pacienții cu scleroză multiplă recurent remisivă în stadiu incipient. Site 305834 - ongoing

42. F. Antochi, C. Tiu

Studiul **MUSICALE MN 39889**. Studiu multicentric noninterventional pentru evaluarea eficacității în practica medicală curentă a Ocrelizumab administrat la pacienții cu scleroză multiplă primar progresivă sau recurentă Site 323071 - ongoing

Studii multicentrice naționale – investigator principal

1. Băjenaru O, Tiu C., Crăciunoiu A, F. Antochi, A. Ene, E. Terecoasă, A. Mergeani, D. Popescu, N. Grecu, O.L. Bajenaru
MOMENT (Cercetari privind **MO**dificările **Me**tabolice cu efecte asupra neurotroficității, asociate bolilor **Ne**urodegenerative și **ne**uroinflama**T**orii cronice) 2015- 2018

Studii multicentrice naționale – membru în echipa de cercetare

1. Bajenaru O, Antochi F, Tiu C, Panea C, Antoniu I, Gherasim R, Roceanu A, Marinescu D
Studiu deschis, controlat, randomizat privind eficacitatea tratamentului cu Sortis (Atorvastatine) in preventia secundara a AVC ischemic
Contract de cercetare cu Parke- Davis
2. Bajenaru O, Tiu C, Ene A
Eficacitatea administrării produsului Neurilege in tratamentul spasticității de origine centrala , 2004
Contract cu Sicomed
3. Bajenaru O, Tiu C, Antochi F
Studiu clinic inițiat de investigator, multicentric, deschis, privind eficacitatea si siguranta administrării Novantrone (mitoxantrona) precum si calitatea vietii la pacientii cu scleroza multipla 2004 2007
4. Bajenaru O, Tiu C, Antochi F, Roceanu A
Studiu observational privind evolutia pacientilor cu angioplastie percutanata cu stent pentru stenoza carotidiana simptomatica sau asimptomatica 2005 – 2007
5. Bajenaru O, Antochi F, Ene A, Popescu B, Tiu C
IWONA – open label, multicentric,prospective, observational, non-interventional, postmarketing surveillance
Contract cu Novartis
6. Bajenaru O, Sanda N, Vargulescu R, Tiu C, Antochi F, Nistor R et al
GNOSIS – inflammation control and the support of the penumbra areas in the ischemic stroke- the protective role of statins. 2007 - 2008.
Studiu inițiat de investigatorul principal.
7. Bajenaru O, Tiu C, Terecoasa E

Studiu național epidemiologic pentru evaluarea prevalenței depresiei și a stării de sănătate a populației adulte cu scleroză multiplă din România. TEVA, 2016-2018

8. O. Băjenaru, C. Tiu, F. Antochi, A. Roceanu

PROCEED- Prospective Phase IV Clinical trial on effectiveness of Rebif treatment of CIS and RMS patients in Romania using electronic device Rebismart, protocol number EMR 200136_583

9. Tiu C

RE – SONANCE: Patient perception of anticoagulant treatment for stroke prevention (Protocol No. 1160.249)

10. O. Băjenaru, Gabriel Prada, Florina Antochi, Cătălin Jianu, Cătălina Tudose, Adina Cuciureanu, Any Axelerad Docu, C. Tiu

GINK-Cog – un studiu multicentric, prospectiv, observațional cu durată de 24 luni, ce își propune să evalueze efectele clinice ale extractului standardizat de Ginko Biloba (EGb71®) la subiecți cu tulburare cognitivă ușoară de tip amnezie (aMCI). Protocol nr. A-38-00240-136; centru 642001, sponsor Ipsen

Prof. Dr Cristina Tiu



27 mar 2023